SMO ClinPlus Co. Ltd.

SHE:301257 China Diagnostics & Research
Market Cap
$595.56 Million
CN¥4.37 Billion CNY
Market Cap Rank
#12090 Global
#2950 in China
Share Price
CN¥55.31
Change (1 day)
-8.21%
52-Week Range
CN¥26.39 - CN¥82.86
All Time High
CN¥82.86
About

SMO ClinPlus CO.,LTD. provides site management services in research development in pharmaceuticals, medical devices, and health-related products in China. The company offers early modeling, preliminary preparation plan trial site initiation, on-site execution, and project management services. SMO ClinPlus CO.,LTD. was founded in 2009 and is based in Shanghai, China.

SMO ClinPlus Co. Ltd. - Asset Resilience Ratio

Latest as of June 2025: 14.36%

SMO ClinPlus Co. Ltd. (301257) has an Asset Resilience Ratio of 14.36% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
CN¥210.73 Million
Cash + Short-term Investments
Total Assets
CN¥1.47 Billion
All company assets
Resilience Assessment
Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2022–2024)

This chart shows how SMO ClinPlus Co. Ltd.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down SMO ClinPlus Co. Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥210.73 Million 14.36%
Total Liquid Assets CN¥210.73 Million 14.36%

Asset Resilience Insights

  • Moderate Liquidity: SMO ClinPlus Co. Ltd. has 14.36% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

SMO ClinPlus Co. Ltd. Industry Peers by Asset Resilience Ratio

Compare SMO ClinPlus Co. Ltd.'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
ADCNF
OTCGREY:ADCNF
Diagnostics & Research 1.12%
Berry Genomics Co Ltd
SHE:000710
Diagnostics & Research 0.45%
NSN Co. Ltd
KQ:031860
Diagnostics & Research 1.72%
JOONGANG DNM Co.Ltd
KQ:051980
Diagnostics & Research 27.26%
GeneMatrix Inc
KQ:109820
Diagnostics & Research 41.52%
Genoray Co. Ltd
KQ:122310
Diagnostics & Research 0.03%
Green Cross Lab Cell Corporation
KQ:144510
Diagnostics & Research 0.18%
Optipharm.CO.LTD
KQ:153710
Diagnostics & Research 20.73%

Annual Asset Resilience Ratio for SMO ClinPlus Co. Ltd. (2022–2024)

The table below shows the annual Asset Resilience Ratio data for SMO ClinPlus Co. Ltd..

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 28.02% CN¥400.58 Million CN¥1.43 Billion -2.79pp
2023-12-31 30.81% CN¥421.14 Million CN¥1.37 Billion +19.06pp
2022-12-31 11.75% CN¥136.38 Million CN¥1.16 Billion --
pp = percentage points